For frail elderly patients, it's crucial to discern if poor performance status stems from disease or comorbidities. A practical approach is to initiate treatment with biologic agents alone. If the patient's status improves, it confirms the cancer is the cause, justifying the subsequent, careful addition of cytotoxic chemotherapy.

For patients over 75 with metastatic gastric cancer, a common practice is to reduce the oxaliplatin dose from 85 to 65 mg/m² and universally omit the 5-FU bolus from the FOLFOX regimen. This pragmatic approach aims to maintain efficacy while minimizing toxicity in a more vulnerable population.

For frail elderly patients with HER2+ gastric cancer, starting with targeted therapy and immunotherapy alone can gauge response and tolerance. Cytotoxic chemotherapy can be added later if the patient's performance status improves, distinguishing disease-related frailty from baseline comorbidities.

When treating elderly patients (e.g., age 80+) with metastatic breast cancer, clinicians may prioritize quality of life over marginal overall survival gains seen in clinical trials. This justifies using a better-tolerated CDK4/6 inhibitor like palbociclib, even though ribociclib has demonstrated a statistical survival benefit, especially when patients have comorbidities or a preference for fewer side effects.

Despite a study showing a minor hazard ratio benefit for a FLOT-like regimen over FOLFOX in the metastatic setting, experts advise against it. The significant increase in toxicity outweighs the small efficacy advantage, especially in symptomatic metastatic patients who are often nutritionally deficient and less able to tolerate aggressive chemotherapy.

Despite being the backbone for new combination therapies in trials like Matterhorn, the FLOT chemotherapy regimen has significant toxicity. Approximately 30% of patients discontinue treatment due to adverse events, and only half manage to complete the post-surgery adjuvant portion, posing a major clinical challenge in real-world settings.

In a phase 2 trial, the combination of zanidatumab and FOLFOX achieved a remarkable 95% response rate after two key modifications were made: adding prophylactic loperamide and dropping the 5-FU bolus. This suggests the bolus adds toxicity without clear benefit in this specific, potent combination.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

As survival times for metastatic gastric cancer patients extend, managing long-term toxicity is paramount. Clinicians typically administer only 6-8 cycles of oxaliplatin to prevent severe, cumulative peripheral neuropathy, allowing for longer, better-tolerated maintenance therapy with biologics.